ADC Therapeutics' (ADCT) Buy Rating Reiterated at HC Wainwright

ADC Therapeutics (NYSE:ADCT - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They presently have a $8.00 price objective on the stock. HC Wainwright also issued estimates for ADC Therapeutics' Q1 2025 earnings at ($0.39) EPS, Q2 2025 earnings at ($0.40) EPS, Q3 2025 earnings at ($0.41) EPS, Q4 2025 earnings at ($0.42) EPS and FY2025 earnings at ($1.62) EPS.

ADCT has been the topic of several other reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of ADC Therapeutics in a research note on Friday, March 7th. Guggenheim reaffirmed a "buy" rating and issued a $10.00 target price on shares of ADC Therapeutics in a research note on Thursday, December 12th. Finally, Stephens increased their price target on ADC Therapeutics from $6.00 to $8.00 and gave the stock an "overweight" rating in a research note on Monday, February 24th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, ADC Therapeutics presently has an average rating of "Buy" and a consensus target price of $7.75.

ADC Therapeutics Stock Down 7.1 %

Shares of ADC Therapeutics stock traded down $0.10 during trading on Monday, hitting $1.24. 469,136 shares of the company were exchanged, compared to its average volume of 452,783. The firm has a 50 day moving average price of $1.64 and a 200 day moving average price of $2.22. The stock has a market capitalization of $119.41 million, a price-to-earnings ratio of -0.52 and a beta of 1.51. ADC Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $5.38.

Remove Ads

ADC Therapeutics (NYSE:ADCT - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.06. The company had revenue of $19.00 million during the quarter, compared to analyst estimates of $19.01 million. Analysts predict that ADC Therapeutics will post -1.69 earnings per share for the current year.

Institutional Investors Weigh In On ADC Therapeutics

A number of institutional investors have recently bought and sold shares of ADCT. Kazazian Asset Management LLC acquired a new position in shares of ADC Therapeutics in the 4th quarter valued at $26,000. Two Sigma Securities LLC purchased a new position in shares of ADC Therapeutics in the 4th quarter worth $30,000. Russell Investments Group Ltd. boosted its holdings in ADC Therapeutics by 122.6% in the fourth quarter. Russell Investments Group Ltd. now owns 16,794 shares of the company's stock valued at $33,000 after acquiring an additional 9,248 shares during the last quarter. Prudential Financial Inc. purchased a new stake in ADC Therapeutics during the fourth quarter valued at about $35,000. Finally, Intech Investment Management LLC purchased a new stake in ADC Therapeutics during the third quarter valued at about $41,000. 41.10% of the stock is currently owned by hedge funds and other institutional investors.

About ADC Therapeutics

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.